Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
Recruiting · Phase 1 · NCT04689048
Conditions: Brain Metastases, Adult, Brain Metastases, Brain Cancer
At a glance
- Research payments reported, 2025
- $10,333
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 20
About the trial
- Sponsor
- Baptist Health South Florida (with Blue Earth Diagnostics)
- Tested
- 18F fluciclovine (drug)
- Dates
- Started 2022-04-04; completion 2027-12
- Results posted
- Not yet
The spread of cancer to the brain is referred to as brain metastases. Brain metastases are a common complication of cancer. This study is being done to determine whether the use of a new imaging agent, 18F-fluciclovine, is able to detect which patients are responding to radiation therapy. In addition, this study will look at the changes of the treated brain metastases using this imaging agent over time.
From ClinicalTrials.gov, last updated 2026-04-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Blue Earth Diagnostics reported $10,333 in research payments for this study in 2025 (2 payments).
Products named: Axumin
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Miami Cancer Institute at Baptist Health $10,333
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.